174 related articles for article (PubMed ID: 19030178)
1. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.
Nedelko T; Arlt VM; Phillips DH; Hollstein M
Int J Cancer; 2009 Feb; 124(4):987-90. PubMed ID: 19030178
[TBL] [Abstract][Full Text] [Related]
2. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
3. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer.
Arlt VM; Stiborová M; vom Brocke J; Simões ML; Lord GM; Nortier JL; Hollstein M; Phillips DH; Schmeiser HH
Carcinogenesis; 2007 Nov; 28(11):2253-61. PubMed ID: 17434925
[TBL] [Abstract][Full Text] [Related]
4. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
5. DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer.
Stiborová M; Arlt VM; Schmeiser HH
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036902
[TBL] [Abstract][Full Text] [Related]
6. Balkan endemic nephropathy: an update on its aetiology.
Stiborová M; Arlt VM; Schmeiser HH
Arch Toxicol; 2016 Nov; 90(11):2595-2615. PubMed ID: 27538407
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.
Slade N; Moll UM; Brdar B; Zorić A; Jelaković B
Mutat Res; 2009 Apr; 663(1-2):1-6. PubMed ID: 19428366
[TBL] [Abstract][Full Text] [Related]
8. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania.
Schmeiser HH; Kucab JE; Arlt VM; Phillips DH; Hollstein M; Gluhovschi G; Gluhovschi C; Modilca M; Daminescu L; Petrica L; Velciov S
Environ Mol Mutagen; 2012 Oct; 53(8):636-41. PubMed ID: 22987305
[TBL] [Abstract][Full Text] [Related]
9. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR.
Arlt VM; Schmeiser HH; Pfeifer GP
Carcinogenesis; 2001 Jan; 22(1):133-40. PubMed ID: 11159751
[TBL] [Abstract][Full Text] [Related]
10. Mutational signature of aristolochic acid: Clue to the recognition of a global disease.
Rosenquist TA; Grollman AP
DNA Repair (Amst); 2016 Aug; 44():205-211. PubMed ID: 27237586
[TBL] [Abstract][Full Text] [Related]
11. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
Stiborova M; Frei E; Arlt VM; Schmeiser HH
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
[TBL] [Abstract][Full Text] [Related]
12. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
13. Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations.
Xiao J; Zhu X; Hao GY; Zhu YC; Hou HJ; Zhang J; Ma LL; Tian Y; Zhang YH
Transplant Proc; 2011 Dec; 43(10):3751-4. PubMed ID: 22172840
[TBL] [Abstract][Full Text] [Related]
14. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model.
Kucab JE; Phillips DH; Arlt VM
FEBS J; 2010 Jun; 277(12):2567-83. PubMed ID: 20553493
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis.
Aydin S; Ambroise J; Cosyns JP; Gala JL
Mutat Res Genet Toxicol Environ Mutagen; 2017 Jun; 818():17-26. PubMed ID: 28477877
[TBL] [Abstract][Full Text] [Related]
16. Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection.
Aydin S; Dekairelle AF; Ambroise J; Durant JF; Heusterspreute M; Guiot Y; Cosyns JP; Gala JL
PLoS One; 2014; 9(9):e106301. PubMed ID: 25184754
[TBL] [Abstract][Full Text] [Related]
17. Ochratoxin A and aristolochic acid involvement in nephropathies and associated urothelial tract tumours.
Pfohl-Leszkowicz A
Arh Hig Rada Toksikol; 2009 Dec; 60(4):465-83. PubMed ID: 20061248
[TBL] [Abstract][Full Text] [Related]
18. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
Grollman AP
Environ Mol Mutagen; 2013 Jan; 54(1):1-7. PubMed ID: 23238808
[TBL] [Abstract][Full Text] [Related]
19. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy.
De Broe ME
Kidney Int; 2012 Mar; 81(6):513-5. PubMed ID: 22373701
[TBL] [Abstract][Full Text] [Related]
20. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.
Arlt VM; Stiborova M; Schmeiser HH
Mutagenesis; 2002 Jul; 17(4):265-77. PubMed ID: 12110620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]